Bikash Chatterjee on Muck Rack

Bikash Chatterjee

Fremont
As seen in: Pharmaceutical Technology, Med Device Online, Pharma Manufacturing, Clinical Leader, Life Science Leader, Bioprocess Online, Pharmaceutical Online, Outsourced Pharma, Cell & Gene, Biosimilar Development and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bikash

Contact Bikash, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

How CDMOs are Creating Strategic Advantages with Emerging Technologies

|
By Bikash Chatterjee
| Tablets & Capsules Magazine Verified
As patient-centered drug design and personalized medicine gain prominence, pharmaceutical companies must navigate more intricate clinical and regulatory landscapes, necessitating greater operational efficiency. In the pharma industry, outsourcing to specialized partners has become common practice, allowing companies to accelerate innovation, streamline workflows and scale cost-effectively, ensuring faster time-to-market while maintaining high-quality drug development and manufacturing standards.
Open in Who Shared Issue with article?

03.13.25 -- Emerging Trends In mAbs Manufacturing

|
By Bikash Chatterjee, Pharmatech Associates, Josh Erickson, Susan Shockey
| Biosimilar Development Verified
Get more biosimilar development insight with our FREE newsletter Newsletter | March 13, 2025 Two key innovations — continuous perfusion in upstream processing and multicolumn chromatography in downstream processing — are having a profound impact on biologics manufacturing. Without high quality data, surface sampling simply becomes another exercise in checking regulatory compliance boxes.
Open in Who Shared Issue with article?

02.20.25 -- Emerging Trends In mAbs Manufacturing In 2025 And Beyond

|
By Bikash Chatterjee, Pharmatech Associates, Andrea Rabellino, Unjulie Bhanot
| Bioprocess Online Verified
BoB@JPM: Ran Zheng, Landmark Bio Ran Zhang was hire number one at Landmark Bio back in 2021. Today, she's CEO of the 70+ employee cell and gene therapy manufacturer. The Business of Biotech caught up with her at the JP Morgan Healthcare Conference in San Francisco for a discussion on Landmark's role in addressing the ATMP patient access and cost reduction challenges.
Open in Who Shared Issue with article?
See all 71 licensed articles (74 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified